This guide covers every condition treated with HBOT, from well-established FDA-approved indications to emerging off-label applications with varying levels of evidence.
FDA-Approved Conditions (14 Indications)
1. Air or Gas Embolism
- What: Gas bubbles in the bloodstream blocking circulation
- Evidence: Emergency indication with decades of clinical use
- Protocol: Immediate HBOT at 2.8 ATA per Navy Treatment Tables
2. Carbon Monoxide Poisoning
- What: CO displaces oxygen from hemoglobin
- Evidence: Strong — standard of care for severe poisoning
- Protocol: Emergency treatment at 2.5-3.0 ATA
3. Gas Gangrene
- What: Clostridial bacterial infection producing gas in tissues
- Evidence: Strong — HBOT directly kills anaerobic bacteria
- Protocol: Emergency, multiple sessions at 3.0 ATA
4. Crush Injury and Compartment Syndrome
- What: Traumatic tissue compression and swelling
- Evidence: Strong for limb salvage
- Protocol: Urgent, multiple sessions at 2.0-2.5 ATA
5. Decompression Sickness
- What: Nitrogen bubbles in blood/tissues from rapid pressure changes (diving)
- Evidence: Gold standard treatment
- Protocol: Navy Treatment Table 6 at 2.8 ATA
6. Diabetic Foot Ulcers
- What: Non-healing wounds in diabetic patients
- Evidence: Strong — most commonly treated condition
- Protocol: 20-40 sessions at 2.0-2.5 ATA
- Insurance: Widely covered with criteria
7-14. Additional FDA Conditions
- Exceptional blood loss anemia
- Intracranial abscess
- Necrotizing soft tissue infections
- Chronic refractory osteomyelitis
- Delayed radiation injury (soft tissue and bone)
- Compromised skin grafts and flaps
- Acute thermal burn injury
- Idiopathic sudden sensorineural hearing loss
Off-Label Conditions (Growing Evidence)
Long COVID
- Evidence level: Strong and growing (10 RCTs, 21 total studies through 2025)
- Protocol: 40 sessions at 2.0 ATA, 5x/week
- Benefits: Improved cognition, sleep, QOL, pain; persistent 1 year
- Insurance: Not covered; $6,000-$12,000 out-of-pocket
Traumatic Brain Injury (TBI)
- Evidence level: Moderate-strong
- Key study: Neuroplasticity induction even years post-injury (PLOS One)
- Protocol: 40-60 sessions at 2.0 ATA
- Benefits: Cognitive improvement, reduced symptoms
- Insurance: Not covered for TBI specifically
Stroke Recovery
- Evidence level: Moderate (mixed results)
- Key study: 2024 meta-analysis of 493 patients showed improved functional outcomes
- Considerations: Timing critical for acute stroke; chronic phase may benefit from neuroplasticity
- Insurance: Not covered
Anti-Aging and Longevity
- Evidence level: Moderate (landmark study, needs replication)
- Key study: 20% telomere lengthening, 37% senescent cell clearance (Aging, 2020)
- Protocol: 60 sessions at 2.0 ATA
- Benefits: Potential biological age reversal
- Insurance: Not covered
Athletic Performance and Recovery
- Evidence level: Moderate
- Key study: 2025 meta-analysis of 299 athletes confirmed recovery benefits
- Protocol: 10-40 sessions at 2.0-2.5 ATA
- Benefits: Accelerated injury healing, reduced inflammation
- Insurance: Not covered
Additional Off-Label Uses
- Autism spectrum disorder (preliminary evidence)
- Fibromyalgia (small studies showing benefit)
- Cerebral palsy (emerging research)
- Lyme disease (limited evidence)
- PTSD (pilot studies)
Evidence Hierarchy
| Condition | Evidence Level | Studies | Insurance |
|---|---|---|---|
| Diabetic wounds | Very strong | Hundreds | Yes |
| CO poisoning | Very strong | Decades of use | Yes |
| Decompression sickness | Very strong | Gold standard | Yes |
| Long COVID | Strong | 21 studies, 10 RCTs | No |
| TBI | Moderate-strong | Multiple RCTs | No |
| Anti-aging | Moderate | Landmark study | No |
| Athletic recovery | Moderate | Meta-analysis | No |
| Stroke | Moderate | Mixed results | No |
Frequently Asked Questions
Which conditions have the strongest evidence for HBOT?
The 14 FDA-approved conditions have the strongest evidence, developed over decades. Among off-label uses, long COVID has the most rapidly growing evidence base with 10 RCTs published through 2025. TBI and anti-aging applications have landmark studies but need larger replication trials. See detailed Shamir long-COVID RCT analysis for the full Shamir-RCT methodology analysis.
Can HBOT cure any of these conditions?
HBOT is not described as a "cure" for any condition. For FDA-approved conditions like diabetic wounds, it significantly improves healing rates. For off-label conditions, it can produce significant symptom improvement and functional gains. Benefits are often maintained long-term but some conditions may require maintenance sessions.
Why isn't HBOT FDA-approved for long COVID or TBI?
FDA approval requires extensive clinical trials and formal application by manufacturers or sponsors. The growing evidence for long COVID and TBI is accumulating, but the formal approval process takes years and significant investment. The evidence base is approaching the threshold where formal approvals may be pursued.
Should I choose HBOT based on my specific condition?
Yes. HBOT works through specific mechanisms (oxygenation, angiogenesis, stem cell mobilization) that are more relevant to some conditions than others. Discuss your specific condition with a hyperbaric medicine physician who can assess whether HBOT is appropriate and recommend an evidence-based protocol.
Where can I find current research on HBOT for my condition?
PubMed (pubmed.ncbi.nlm.nih.gov) is the primary database for medical research. Search "hyperbaric oxygen therapy [your condition]" for current studies. The Undersea and Hyperbaric Medical Society (UHMS) also maintains clinical guidelines and research summaries.
Find HBOT Centers Near You
Browse our complete directory of HBOT centers to find facilities experienced in treating your specific condition.
-- The HBOT Finder Team
Medical Disclaimer: This article is for informational purposes only. HBOT should be discussed with a qualified physician for your specific condition.
Affiliate Disclosure: Some links may be affiliate links.